Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?

CTAD Presentation Is First Detailed Data

 
• By Mandy Jackson
Alzheimer's disease on MRI
Amyloid-related imaging abnormalities were among the most common adverse events • Source: Shutterstock

More from Clinical Trials

More from R&D